Eli Lilly and Company (NYSE:LLY) Shares Sold by Jamison Private Wealth Management Inc.

Jamison Private Wealth Management Inc. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,879 shares of the company's stock after selling 784 shares during the period. Eli Lilly and Company makes up 2.6% of Jamison Private Wealth Management Inc.'s portfolio, making the stock its 6th biggest holding. Jamison Private Wealth Management Inc.'s holdings in Eli Lilly and Company were worth $17,244,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $43,000. FPC Investment Advisory Inc. increased its stake in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $48,000. Highline Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after purchasing an additional 24 shares in the last quarter. Finally, Capital A Wealth Management LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $63,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective for the company. Guggenheim restated a "buy" rating and set a $936.00 target price on shares of Eli Lilly and Company in a research report on Friday. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $1,011.79.

Eli Lilly and Company Stock Up 1.1%

Shares of NYSE:LLY traded up $8.33 during mid-day trading on Tuesday, reaching $778.97. 2,786,035 shares of the stock were exchanged, compared to its average volume of 3,666,258. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a market cap of $738.26 billion, a P/E ratio of 63.38, a P/E/G ratio of 1.11 and a beta of 0.41. The stock's 50 day simple moving average is $780.81 and its 200-day simple moving average is $800.36.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the firm posted $2.58 earnings per share. The firm's quarterly revenue was up 45.2% on a year-over-year basis. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.